Starling Oncology, Inc. (STLN) · Sep 1, 2026 · Exec change

Starling Oncology director exits 2027 race, steps down from board leadership

Director departure — Hively will not stand for re-election at the 2027 annual meeting

Brad Hively will not seek reelection and immediately leaves Starling Oncology’s vice-chair and committee roles, without citing company disagreement.

This is a governance transition, not an operating update. Brad Hively plans to leave Starling Oncology’s board after the 2027 annual meeting and has already stepped down as vice chairman and from all board committees.

The immediate change is broader than a future director retirement. Hively is expected to remain a director until the annual meeting, but no longer holds the vice-chair role or committee assignments. 〔0〕

Relative to expectations, there is no clean beat-or-miss benchmark. The filing gives no indication of an operational, financial, or strategic impact, and explicitly says the decision was not caused by a disagreement with the company. 〔1〕

Net read: a new but currently neutral board-change disclosure. The material item to monitor is who replaces Hively as vice chairman and on the committees, particularly Compliance, before the 2027 annual meeting.

What to watch next

2027 annual meeting and board succession

Original filing on SEC EDGAR

More Starling Oncology, Inc. news

Starling Oncology director exits 2027 race, steps down from board leadership | STLN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.